BCL2L1 and lung carcinoma: RBM10 deletion is associated with resistance to EGFR inhibitors in EGFR-mutant lung cancer, likely due to a reduced BclxS/BclxL ratio, which diminishes apoptosis induced by EGFR inhibitors 15.